A Case of Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter 2 Inhibitor.
10.4093/jkd.2015.16.4.310
- Author:
Jae Hyuck JUN
1
;
Kyung Jin CHOE
;
Yeong Min WOO
;
Ye Rim PARK
;
Yoon Kyoo PARK
;
Won Jun KIM
;
Myoung Sook SHIM
;
Jin Yeob KIM
Author Information
1. Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. kozmozman@gnah.co.kr
- Publication Type:Case Report
- Keywords:
Diabetes mellitus;
Ketosis;
Sodium-glucose cotransporter 2
- MeSH:
Aged;
Anorexia;
Blood Glucose;
Dehydration;
Diabetes Mellitus;
Diabetes Mellitus, Type 2;
Diabetic Ketoacidosis*;
Diarrhea;
Diet;
Female;
Glucose;
Humans;
Hydrogen-Ion Concentration;
Ketosis;
Weight Loss
- From:Journal of Korean Diabetes
2015;16(4):310-314
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral antihyperglycemic drugs; inhibition of the cotransporter allows for increased renal glucose excretion that consequently leads to reduced plasma glucose level. We report a rare case of a 73-year-old woman with type 2 diabetes mellitus who developed severe ketoacidosis caused by an SGLT2 inhibitor. At admission, severe ketoacidosis with arterial PH 6.99 was observed, though her serum glucose level of 232 mg/dL was not excessively high. It is necessary to pay attention to patients with type 2 diabetes being treated with an SGLT2 inhibitor, as anorexia, diarrhea, dehydration, and weight loss can develop in conjunction with a high fat/protein diet.
